Nkarta Q1 2023 Earnings Report
Key Takeaways
Nkarta reported cash and cash equivalents of $332.1 million as of March 31, 2023. The company's net loss for the quarter was $30.8 million, or $0.63 per share. Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Clinical updates on track for NKX101 in the second quarter of 2023 and NKX019 in the second half of 2023.
Nkarta plans to present additional clinical data in the second quarter of 2023 from its ongoing Phase 1 clinical trial of NKX101 in patients with relapsed or refractory acute myeloid leukemia (r/r AML).
Nkarta plans to present additional clinical data in the second half of 2023 from its ongoing Phase 1 clinical trial of NKX019 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Cash and cash equivalents totaled $332.1 million on March 31, 2023, expected to fund operations into 2025.
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.